Clinical Trials on Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection in Hong Kong

Total 21 results

Chinese University of Hong Kong

Terminated

Novel SARS-CoV-2 Point-of-care Testing

SARS-CoV2 Infection

Hong Kong
Chinese University of Hong Kong

Completed

Identifying Risks of COVID-19 Outbreaks in Work Settings and the Implications for Control Measures

Intention to Get SARS-CoV-2 Vaccination | Intention to Get SARS-CoV-2 Antibody Test

Hong Kong
Chinese University of Hong Kong

Enrolling by invitation

COVID-19 Serology in People Living With HIV in Hong Kong

HIV Infections | SARS-CoV-2 Infection | Vaccination; Infection

China
BioNTech SE

Completed

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

COVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)

United States, Germany, Turkey, South Africa
AstraZeneca

Active, not recruiting

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (TRUST)

SARS-CoV-2

United States, Belgium, United Kingdom, Brazil, Germany
Mahidol University
Chulalongkorn University; Ministry of Health, Thailand; Yuvabadhana foundation; Zero COVID Thailand

Completed

The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community

Coronavirus Infections | Covid19 | SARS-CoV-2 | Community Transmissions

Thailand
AstraZeneca

Active, not recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
Gilead Sciences

Approved for marketing

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

SARS-CoV2 Infection

United States, Israel, Belgium, Spain, Australia, Denmark, Italy, Germany, France, Portugal, United Kingdom, Poland, Switzerland, Canada, Austria, Cyprus, Czechia, Estonia, Greece, Hungary, Iceland, Ireland, Lithuania, Netherlands, Romania and more
Novavax

Completed

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

COVID-19 | SARS-CoV-2 Infection

United States
Pfizer

Completed

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

SARS-CoV-2 Infection

United States
Invivyd, Inc.

Active, not recruiting

A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2

COVID-19 | SARS-CoV-2

United States
Shionogi

Recruiting

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection (SCORPIO-PEP)

SARS-CoV-2 Infection

Japan, United States
Medicago

Active, not recruiting

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

SARS-CoV-2 Infection

United States, Canada, United Kingdom, Argentina, Brazil, Mexico
BioNTech SE
Pfizer

Completed

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

COVID-19 | SARS-CoV-2 Infection

United States, Germany, Turkey, South Africa, Argentina, Brazil
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Healthy Participants

United States, Moldova, Republic of, Romania
BioNTech SE
Pfizer

Completed

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

COVID-19 | SARS-CoV-2 Infection

United States, Brazil, South Africa, Germany, Canada, Israel
Regeneron Pharmaceuticals

Terminated

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

SARS-CoV-2

United States
Shionogi
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 (SCORPIO-HR)

SARS-CoV-2 Infection

United States, India, Uganda, Poland, Philippines, Thailand, Pakistan, South Africa, Argentina, Brazil, Colombia, Ghana, Japan, Kenya, Malawi, Mexico, Turkey
Atea Pharmaceuticals, Inc.

Active, not recruiting

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

COVID-19 | SARS CoV 2 Infection

United States, Argentina, Brazil, Canada, Germany, India, Japan, Latvia, Mexico, Netherlands, Pakistan, Philippines, Romania, South Africa, Spain, Sweden, Tunisia, Turkey, United Kingdom
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1083 (SARS-Cov-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Influenza | SARS-CoV-2

United States
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates

Clinical Trials on Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations